We aim to evaluate 3-year effects of ocrelizumab (humanized anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes, neutrophils and immunoglobulins: (1) when compared with pre-infusion assessment; (2) over the course of treatment; and (3) possible clinical correlates of the observed immunological modifications.
Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study / Capasso, N., Palladino, R., Cerbone, V., Spiezia, A.L., Covelli, B., Fiore, A., Lanzillo, R., Carotenuto, A., Petracca, M., Stanziola, L., Scalia, G., Brescia Morra, V., Moccia, M.. - In: JOURNAL OF NEUROLOGY. - ISSN 0340-5354. - (2022). [10.1007/s00415-022-11350-1]
Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study
Petracca, Maria;
2022
Abstract
We aim to evaluate 3-year effects of ocrelizumab (humanized anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes, neutrophils and immunoglobulins: (1) when compared with pre-infusion assessment; (2) over the course of treatment; and (3) possible clinical correlates of the observed immunological modifications.| File | Dimensione | Formato | |
|---|---|---|---|
|
s00415-022-11350-1.pdf
accesso aperto
Note: Capasso_Ocrelizumab effect_2022
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
1.03 MB
Formato
Adobe PDF
|
1.03 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
